Phase
Condition
Chronic Fatigue Syndrome
Pain (Pediatric)
Fibromyalgia
Treatment
Medical Food - Anhydrous Enol-Oxaloacetate
Placebo
Clinical Study ID
Ages 18-70 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Patients who meet all of the following criteria are eligible to participate in thestudy:
Provision of signed and dated informed consent form
Ability to read, understand or speak English
Diagnosed with ME/CFS and meet the IOM Diagnostic Criteria for ME/CFS (2015)
Relatively stable state of illness for the past 3 months that is characterizedby >2 and <6 hours of daily upright activity
Male or female, between the ages of 18 and 65 years old
No evidence of active infection with SARS-CoV-2 documented by a negative testat Visit 1
Agree to refrain from taking medications that would affect assessment of theeffectiveness of study dietary supplement for the duration of the study
Females of childbearing potential should be on adequate contraception such asoral, implantable, injectable or transdermal hormonal contraceptives (shouldhave been used for a minimum of one full cycle prior to administration of studydrug), intrauterine devices (IUD), vasectomized partner, double barrier method (male or female condom, sponge, diaphragm or vaginal ring with simultaneous useof spermicidal jelly or cream)
Each patient of child-bearing potential must have a negative urine pregnancytest at Visit 1. The urine test at Visit 1 must both be confirmed negativeprior to randomization. Women of child-bearing potential will have a urinepregnancy test at each visit (2-4) and it must be negative to continue. Womenwho are confirmed to be of non-childbearing potential do not require pregnancytesting. To be considered of non-child-bearing potential, the patient must be:post-menopausal (defined as no menses for at least one year); or surgicallysterile (s/p hysterectomy, bilateral oophorectomy or bilateral tubal ligationat least 6 months prior to randomization); or at least 3 months s/p anon-surgical permanent sterilization procedure
History of fatigue and post-exertional malaise (PEM)
Stated willingness to comply with all study procedures and remain available forthe study duration
Have mobile (smart) phone and access to the internet
Willingness to wear a device on their ankle
Exclusion
Exclusion Criteria:
A patient who meets any of the following criteria will be excluded fromparticipation in this study:
A positive rapid COVID-19 antigen test at Visit 1
Alternate medical or psychiatric illness that could explain the ME/CFS symptoms
Severe ME/CFS with less than 2 hours of upright activity a day
Active or uncontrolled co-morbidities which in the opinion of the PI mayinterfere with the ability of the patient to participate in the study.Co-morbidities may include acute infection, Crohn's disease, diabetes mellitus (Type 1 or Type 2, evidenced by a history of HbA1c > 7 at any time),Guillain-Barre syndrome, lupus, multiple sclerosis, myasthenia gravis,rheumatoid arthritis, or other such diseases that may be exclusionary.Particularly conditions or medications that cause immunodeficiency orimmunosuppression will be excluded. Examples of such conditions can be found inthe tables "Causes of Secondary Immunodeficiency" and "Some Drugs that CauseImmunosuppression" in the "Merck Manual"
Body Mass Index > 35
Participating in another clinical treatment trial, or symptoms improving as aresult of treatment intervention in the past 3 months
Current treatment with stimulants including methylphenidate,amphetamine-dextroamphetamine, lisdexamfetamine, modafinil, armodafinil
Pregnancy, or while breast feeding. Women should not be enrolled within 6months of giving birth and within 3 months of cessation of breast feeding.
History of:
Major depression with psychotic or melancholic features before the diagnosis ofME/CFS, or active depression (major depression with psychotic or melancholicfeatures) as determined by self-report
Untreated endocrine diagnoses including hypothyroidism (Hashimoto's, etc.), Grave'sdisease, adrenal insufficiency, hypogonadism (testosterone deficiency), diabetesmellitus or insipidus
Significant head injury in the last 3 years, concussion with loss of consciousness,brain surgery, an automobile accident with head/neck injury, and/or other traumaticbrain injury
A supra-ventricular tachycardia or ventricular tachycardia, e.g., atrialfibrillation or flutter, paroxysmal atrial fibrillation, junctional tachycardia,ventricular tachycardia
Symptomatic hypotension defined as rested sitting systolic BP < 100 mmHg or restedsitting diastolic BP < 60 mmHg
Substance abuse in the past 12 months as determined by self-report • Improvement inoverall ME/CFS symptoms as a result of any treatment intervention in the past 3months
Study Design
Study Description
Connect with a study center
Bateman Horne Center
Salt Lake City, Utah 84102
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.